Table 6 Different answers to the knowledge of COPD between intervention group and control group
Intervention | Control | P value | |
|---|---|---|---|
Group(n = 49) | Group(n = 61) | ||
Prevalence of COPD in China | NS | ||
Average of reported prevalence | 11.2% | 13.6% | |
Average of reported prevalence | 0.2–50.0% | 0.2–70.0% | |
Most important risk factors of COPD (% of respondents) | NS | ||
Smoking | 91.8% | 95.1% | |
Infection | 8.2% | 4.9% | |
Most valuable indication for early diagnosis of COPD (% of respondents) | NS | ||
Symptoms | 16.3% | 18.0% | |
Physical examination | 2.0% | 8.2% | |
Spirometry | 89.8% | 86.9% | |
Chest x-ray | 4.1% | 8.2% | |
First choice exam for confirming diagnosis (% of respondents) | NS | ||
Spirometry | 55.1% | 54.1% | |
Medical history (chronic bronchitis or emphysema) | 22.4% | 23.0% | |
Symptoms | 20.4% | 24.6% | |
First-line prescribed medicine for COPD | 0.009 | ||
Beta2-agonists | 49.0% | 23.0% | |
Combined beta2-agonists with corticosteroid | 30.6% | 42.7% | |
Inhaled corticosteroid | 8.2%% | 11.8% | |
Anticholinergic | 4.1% | 11.0% | |
Theophylline | 6.1% | 8.2% | |
First-line prescribed medicine for COPD exacerbation (% of respondents) | 0.004 | ||
Antibiotics | 42.9% | 31.1% | |
Oral corticosteroid | 14.3% | 21.3% | |
Combined beta2-agonists with corticosteroid | 14.3% | 19.7% | |
Beta2-agonists bronchodilators | 24.5% | 11.5% | |
Anticholinergic agents | 2.0% | 3.3% | |
Theophylline | 0.0% | 4.9% | |
Provide smoking cessation counseling | NS | ||
Always | 97.0% | 98.0% | |
Occasionally | 3.0% | 2.0% | |
Suggestions for taking influenza vaccine | 0.03 | ||
Always | 63.3% | 47.5% | |
Occasionally | 36.7% | 52.5% | |
Indications for inhaled corticosteroid | NS | ||
Know well | 40.8% | 27.9% | |
Know moderately | 26.6% | 39.3% | |
Know poor | 32.6% | 32.8% | |